NDC 55390-031-10                                   50 mg in 2 mL (10 vials to a carton)

NDC 55390-032-10                                   100 mg in 4 mL (10 vials to a carton)

NDC 55390-033-10                                   200 mg in 8 mL (10 vials to a carton)

NDC 55390-034-10                                   250 mg in 10 mL (10 vials to a carton)

Methotrexate for Injection, USP (preservative free) is supplied in a 1 gram, single-dose vial of lyophilized powder containing 1 gram methotrexate as thebase in the following package strength:

NDC 55390-143-01                                   1 gram Vial (individually boxed)

Store at room temperature 20° to 25°C (68° to 77°F). See USP controlled room temperature. Protect from light.
REFERENCES
Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents,U.S. Government Printing Office, Washington, D.C. 20402.
AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA, March 15, 1985.
National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc. D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Ave., Boston, Massachusetts 02115.
Clinical Oncological Society of Australia; Guidelines and Recommendations for Safe-Handling of Antineoplastic Agents. Med J Australia 1: 426-428, 1983.
Jones RB et al. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA-A Cancer Journal for Clinicians : Sept/Oct,258-263, 1983.
American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 47:1033-1049, 1990.
Controlling occupational exposure to hazardous drugs (OSHA Work-Practice Guidelines). AM J Health Syst Pharm 1996: 53: 1669-1685.
Manufactured by:                                                            &nb